Wall Street Breakfast

The Fed’s favorite inflation gauge adds to the cooling inflation evidence (0:15). Biogen (BIIB) buys a rare disease drugmaker (3:25). It has never been cheaper to hedge against S&P losses (4:55).

Read a transcript of this episode at Seeking Alpha.

Show Links

Employment cost index eases slightly more than expected in Q2
Dividend Roundup: Wells Fargo, Visa, IBM, Hasbro, and more
Exxon slips after Q2 miss; results helped by higher Permian, Guyana production
Palantir Technologies rises as Wedbush says it's on 'golden track to success'
Meta said to plan features to boost retention at Threads as more than half users quit
Procter & Gamble gains after organic sales, margins shine in FQ4
Chevron confirms Q2 results, expects annual production at low end of guidance